全球發售 杭州德適生物科技股份有限公司 Hangzhou Diagens Biotechnology Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 02526 獨家保薦人、保薦人兼整體協調人、整體協調人、 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示：閣下如對本招股章程的任何內容有任何疑問，應徵詢專業獨立意見。 Hangzhou Diagens Biotechnology Co., Ltd. 杭州德適生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 股份代號 : 2526 獨家保薦人、保薦人兼整體協調人、整體協調人、 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 | HILATAL INTEDNATIONAL | | --- | 整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 聯席賬簿管理人及聯席牽頭經辦人 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本招股章程的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明 確表示概 ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內容而 引致的任何損失承擔任何責任。 Hangzhou Diagens Biotechnology Co., Ltd. 杭州德適生物科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會的要求而刊 發，僅用作向香港公眾人士提供資料。 本聆訊後資料集為草擬本，其所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即表 示 閣下知悉、接納並向本公司、其各自保薦人、整體協調人、顧問及包銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公 司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件所 載資料作出投資決定； (b) 在聯交所網站登載本文件或 ...

Core Insights - The article highlights the innovative application of AI and robotics in healthcare, specifically at Changzhou First People's Hospital, showcasing how technology enhances patient care and operational efficiency [1][2][10]. Group 1: AI and Robotics Implementation - Changzhou First People's Hospital has introduced humanoid robots, "Zhenzhen" and "Rurur," to assist with patient navigation and information queries, marking a new application of humanoid robots in Chinese hospitals [1]. - The hospital's AI system has provided over 84,000 interactions, integrating multiple functions such as pre-examination, information queries, and entertainment [1]. - Approximately 43%-45% of outpatient electronic medical records are now generated with AI assistance, with a goal to exceed 50% soon [10]. Group 2: Efficiency and Workflow Improvements - AI technologies have improved diagnostic efficiency in pathology by 30%, with systems achieving a diagnostic accuracy that meets national quality control standards [7]. - The AI imaging system enhances the detection of conditions like lung nodules and liver tumors, achieving a sensitivity of over 94% [7]. - The hospital's AI-assisted documentation allows doctors to spend more time with patients, as voice recognition technology generates draft medical records from conversations [3][10]. Group 3: Logistics and Transportation Innovations - The hospital has established a 5G-A drone medical supply route, reducing transport time for medical materials from 26 minutes to 7 minutes, significantly improving logistics efficiency [8]. - Four drone routes have been established, with plans to add 2-3 more, facilitating timely delivery of medical supplies between healthcare facilities [8]. Group 4: Future Directions and Scalability - Changzhou First People's Hospital aims to develop specialized AI applications for various departments, including finance and clinical specialties, by 2026 [14]. - The hospital is exploring the potential to replicate its AI model in other regional hospitals, providing a comprehensive AI practice solution that includes technology selection and process redesign [12][14]. - The hospital's approach emphasizes collaboration with multiple tech companies to tailor AI solutions to specific healthcare needs, rather than relying on a single vendor [13].

Core Insights - The article discusses the rapid adoption of AI health consultation applications during the Spring Festival, highlighting the competitive landscape among platforms like Yuanbao, Qianwen, Doubao, and Ant Group's Aifuku, which have seen significant user engagement in health-related scenarios [1][8][17] - The article emphasizes the need for regulatory clarity and compliance as AI health consultation tools gain popularity, raising concerns about the boundaries of medical advice and user privacy [2][9][11][17] User Engagement and Market Trends - Qianwen has surpassed 70 million daily active users (DAU), while Doubao is at a similar level, and Yuanbao has nearly 20 million DAU; Ant Aifuku answers health inquiries approximately 10 million times daily [1][8] - Users are increasingly relying on AI for health consultations, especially during the holiday season when traditional medical visits are less favored [5][6][8] AI Application in Health Consultation - AI models are being utilized for health education, light symptom consultation, chronic disease management, and post-diagnosis guidance, indicating a solid application framework [7][17] - However, the term "AI diagnosis" is considered overly ambitious, as AI cannot fully replace professional medical diagnosis [7][17] Regulatory and Compliance Challenges - The article highlights the legal risks associated with AI providing specific medical advice, which could be classified as medical practice, thus requiring careful navigation of compliance regulations [9][11] - User privacy concerns are significant, as many users may unknowingly share sensitive health information, raising issues about data protection and consent [10][11] Future Directions and Sustainability - The integration of AI in healthcare is expected to evolve with clearer regulations and improved technology, potentially leading to personalized health management solutions [12][17] - The article suggests that the future of AI in healthcare will depend on balancing user acquisition costs with sustainable business models, focusing on meeting unmet health needs through effective service delivery [15][16][17]

Group 1 - The main shareholder of iFlytek Medical Technology has extended the lock-up period for one year until December 29, 2026, demonstrating confidence in the company's long-term development and potentially stabilizing market expectations [2] - iFlytek Medical won a significant national project worth 428 million yuan for AI application in healthcare, marking a shift from traditional software delivery to a "model as a service" approach, which may lead to sustained revenue and strengthen its industry position [3] - The AI healthcare sector is expected to experience a large-scale application wave by 2026, with iFlytek Medical positioned to benefit from policy-driven order growth and market expansion [4] Group 2 - The company continues to optimize its self-developed "Spark" medical model, maintaining industry leadership in general auxiliary diagnosis and health consultation, with technology upgrades and clinical implementation expected to enhance monetization capabilities [5] - In the first half of 2025, the company reported a revenue increase of 30.26% to 299 million yuan, with a net loss reduction of 42.86%, indicating potential for improved profitability as medical model orders are expected to materialize in 2025 [6]

Core Insights - The "Artificial Intelligence + Healthcare" ecosystem co-construction seminar in Nanhai District, Foshan, marks a significant step towards standardized and scalable development in smart healthcare [1] - The Nanhai District's framework emphasizes a collaborative approach involving technology breakthroughs and deepening application scenarios to enhance healthcare services [3][4] Group 1: Framework and Mechanism - The framework is built on a "one body, two wings, and three-wheel drive" mechanism, focusing on "people's health" as the core [3] - The "one body" aspect aims to shift healthcare services from a treatment-centered model to a health-centered model, providing comprehensive health services throughout the life cycle [3] - The "two wings" consist of technological advancements and application scenario deepening, ensuring that AI technology is rooted in real healthcare needs [3] Group 2: Key Tasks and Implementation - Four key tasks have been identified: solidifying the "intelligent base," deepening "smart scenarios," constructing an "industrial ecosystem," and innovating "system mechanisms" [4] - The focus on "intelligent base" includes exploring market-oriented reforms for medical data and computational resources [4] - The "smart scenarios" aim to extend AI applications from hospitals to communities, covering the entire health service process [4] Group 3: Practical Outcomes and Innovations - The implementation of the AI-native smart healthcare system has served 126,700 patients, reducing error rates by 20% and improving medical record quality by 60% [6] - The use of the Yuan Nao Qi Zhi EPAI platform facilitates the development of medical intelligent systems, allowing for rapid product development and integration with existing hospital systems [7] - The ecosystem aims to transform national AI strategies into practical, assessable, and replicable grassroots practices, addressing the gap between clinical needs and technological development [7][8]

Core Viewpoint - The integration of AI in healthcare is rapidly advancing, with significant potential benefits in diagnostics and treatment, but it also raises concerns about accuracy, practicality, and the impact on medical professionals' skills [1][5][9]. Group 1: AI Applications in Healthcare - AI is being utilized in various medical applications such as diagnostic assistance, medical record writing, and pre-consultation, with ongoing developments supported by government initiatives [1][2]. - The average accuracy of prenatal diagnosis for congenital defects is only 30%-60%, indicating a significant opportunity for AI to improve outcomes in cases like congenital diaphragmatic hernia [2][7]. - AI has shown high efficiency in areas like image recognition, pathology interpretation, and chronic disease management, which can reduce diagnostic time and human error [3][9]. Group 2: Concerns and Challenges - There are concerns that reliance on AI may lead to a decline in the diagnostic skills of younger doctors, as they may become overly dependent on AI tools [5][6]. - The accuracy of AI is not guaranteed, and it is essential for doctors to maintain their diagnostic authority and critical thinking when using AI [5][6]. - Challenges include the lack of a mature reimbursement system for AI-assisted diagnostics and the need for funding and support for AI development in healthcare [8][9]. Group 3: Regulatory and Development Recommendations - Recommendations include establishing a clinical access and evaluation system for AI medical products, ensuring safety and efficacy in real-world applications [9][10]. - It is suggested that pilot programs be initiated in community health centers and secondary hospitals to demonstrate the effectiveness of AI applications in healthcare [10]. - The government is encouraged to integrate AI into health city and digital governance initiatives to promote collaborative development among industry, hospitals, research, and regulation [10].

Core Insights - Japan has reported over 13,000 syphilis cases for four consecutive years, raising concerns about the rising infection rates in other regions, including Guangdong, China [1] - Guangdong Province has seen a 12.4% decrease in new syphilis cases from January to November 2025 compared to the same period in 2024, with Guangzhou reporting a similar decline [1][2] Summary by Sections Syphilis Infection Trends - The number of new syphilis cases in Guangdong from January to November 2025 decreased by 9,704 cases, marking a 12.4% year-on-year decline [1] - In Guangzhou, the report of syphilis cases also showed a 12.4% decrease during the same period, indicating effective control measures [1][2] Characteristics of Syphilis Cases - A significant proportion of syphilis cases in Guangzhou are latent, accounting for 90%-92% of reported infections [2] - Latent syphilis patients test positive for antibodies but show no clinical symptoms, complicating timely diagnosis and treatment [2] Demographics of Syphilis Patients - High-risk groups for syphilis in Guangzhou include individuals over 60 years old and sexually active young adults, with a higher prevalence among males [2] Digital Health Innovations - The Guangzhou Skin Disease Hospital has implemented a digital platform, "Yangcheng Medical Visit," which integrates risk assessment, online referrals, and offline consultations, enhancing patient management [3] - This platform has conducted 1,324 risk assessments and identified 705 high-risk individuals, providing valuable health information and services [3] Diagnostic and Treatment Advances - The hospital has developed a novel nested real-time quantitative PCR (NR-PCR) testing method for diagnosing neurosyphilis, achieving high sensitivity [4] - Research has optimized treatment protocols for pregnant women, demonstrating no difference in treatment outcomes between one and two treatment courses, thus preventing overtreatment [4] Ongoing Challenges and Regulatory Support - Despite significant progress, syphilis remains one of the most reported infectious diseases in Guangzhou, necessitating continued vigilance in prevention efforts [5] - The new "Guangdong Province Maternal and Child Health Management Regulations" aims to eliminate mother-to-child transmission of syphilis, HIV, and hepatitis B, with a screening rate of over 99% for pregnant women in hospitals [5]

Core Insights - The article discusses the emergence and growth of Internet hospitals in China, highlighting their role in providing convenient and efficient medical services, especially during the COVID-19 pandemic [1][14] - Internet hospitals are seen as a new model in the healthcare system, addressing issues like access to care and hospital transformation [1][14] Industry Overview - Internet hospitals are platforms that integrate online consultations, prescriptions, payments, and drug delivery, connecting patients with healthcare providers [4] - The services offered by Internet hospitals include remote diagnosis, post-hospital management, and health management [4] Industry Development History - The first Internet hospital in China was established in 2015, marking a significant milestone in the integration of healthcare and technology [9] - The COVID-19 pandemic accelerated the growth of Internet hospitals, with over 500 new hospitals established in 2020 alone [1][14] - By October 2022, there were over 2,700 Internet hospitals in China, serving more than 25.9 million patients [1][14] - Projections indicate that by the end of 2024, the number of Internet hospitals will reach 3,340, providing over 100 million consultations annually [1][14] Industry Policies - The Chinese government has increasingly recognized and supported Internet hospitals, leading to a period of policy benefits [11] - Recent policies aim to enhance the integration of artificial intelligence in healthcare, with a goal of widespread implementation by 2030 [11] Industry Value Chain - The upstream of the Internet hospital industry involves medical equipment and information technology, while the midstream consists of solution integrators [12] - The downstream primarily includes patients who utilize these services [12] User Scale and Usage Rate - As of December 2024, the user base for Internet healthcare in China reached 418 million, with a usage rate of 37.7% [13] - By June 2025, the user scale is expected to be 393 million, with a usage rate of 35% [13] Key Companies in the Industry - Notable companies in the Internet hospital sector include Ping An Good Doctor, JD Health, Alibaba Health, and WeDoctor, among others [2][15] - Ping An Good Doctor reported a revenue of 1.278 billion yuan in the first half of 2025, marking a year-on-year growth of 20.23% [15] - JD Health's revenue from health product sales reached 29.331 billion yuan in the first half of 2025, with a growth of 22.67% [17] Challenges Facing the Industry - Issues such as patient information sharing, cross-regional medical insurance reimbursement, and regulatory frameworks remain significant challenges for Internet hospitals [18][19][20] - The complexity of online diagnosis and potential medical risks also pose challenges that need to be addressed [21] Future Trends - The future of Internet hospitals is expected to focus on personalized health management driven by data and AI technologies [22] - Remote medical services will become standardized and integrated into the healthcare system, enhancing accessibility and efficiency [23] - A seamless integration of online and offline services will create a comprehensive healthcare ecosystem centered around patient needs [24]

Core Viewpoint - The pharmaceutical sector, particularly companies integrating AI technologies, has shown significant growth, with Ark Health experiencing a surge of over 76% in stock price, while WuXi AppTec and WuXi Biologics led the blue-chip stocks with notable gains [2][8]. Group 1: Market Performance - The Hang Seng Index rose by 0.9% to close at 26,848.47 points, with a total market turnover of HKD 315.19 billion, an increase from HKD 306.22 billion in the previous trading day [2]. - Among the constituents of the Hang Seng Index, 53 stocks increased while 33 declined, with WuXi AppTec rising by 8.30% and WuXi Biologics by 5.85% [4]. - Notable stock performances included Alibaba, which increased by 3.63%, and China Life, which rose by 3.51% [4]. Group 2: Company Highlights - Ark Health's stock opened with a peak increase of 76.37%, closing at HKD 3.93 per share, marking a daily increase of 65.8% due to its collaboration with Tencent Health in the "AI + Chronic Disease Management" sector [8][9]. - WuXi AppTec's stock price surged by 9.66% to close at HKD 120 per share, driven by a positive earnings forecast indicating a projected net profit growth of approximately 102.65% for 2025 [10][12]. - WuXi Biologics also saw a significant increase, with a maximum rise of 6.92%, closing at HKD 39.78 per share, as the company prepares to present at the 44th Annual J.P. Morgan Healthcare Conference [16][17]. Group 3: Financial Projections - WuXi AppTec's earnings forecast includes an expected revenue of approximately HKD 45.46 billion for 2025, reflecting a year-on-year growth of about 15.84%, with adjusted net profit projected at HKD 14.96 billion, a 41.33% increase [12][13]. - WuXi Biologics anticipates signing a record 209 new projects in 2025, with a focus on expanding its commercial pipeline and maintaining a positive outlook for revenue growth in 2026 [20].